Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1J01GB01----1件: 299
2J05A F01----1件: 135
3J05AG04----1件: 18
4J07AH07----1件: 14
5J1081----1件: 56
6J695----1件: 96
7J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----1件: 96
8JAK 3----1件: 46
9JAK 3 Ritlecitinib----1件: 46
10JAK inhibitor----2件: 46, 50
11JAK1 / JAK2 Inhibitor----1件: 46
12JAK1 / JAK2 Inhibtor----1件: 46
13JAKi----1件: 46
14Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets1件: Acetylcysteine1件: D00221 --1件: 85
15Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets1件: Acetylcysteine1件: D00221 --1件: 85
16Jaktinib Hydrochloride Tablets----1件: 271
17Janus Kinase Inhibitor----2件: 46, 97
18Jardiance1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-1件: 65
19JBT-101----4件: 49, 50, 51, 299
20JBT-101 (lenabasum)----1件: 299
21JBT101----1件: 299
22Jevity 1.0----1件: 2
23Jevity 1.5----1件: 2
24JHL1101----1件: 46
25Jianpixiaozhong particles and Wuse Dietotherapy----1件: 222
26Jinarc1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
27JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
28JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
29JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
30JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
31JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
32Jinarc - Tolvaptan tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
33Jinarc 15 mg tablets, Jinarc 45 mg tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
34Jinarc 30 mg Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
35Jinarc 30 mg tablets, 90 mg tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
36Jinarc 30 mg tablets, Jinarc 60 mg tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
37Jinarc® 15mg Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
38Jinarc® 30 Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
39Jintropin AQ----1件: 78
40JKB-122----1件: 95
41JKB-122 in capsule or tablet form----1件: 95
42JM----2件: 6, 13
43JM-010----1件: 6
44JM-4----1件: 13
45JNJ 38518168----1件: 46
46JnJ 54767414----1件: 28
47JNJ-16240159-AAC----1件: 46
48JNJ-31001074----1件: 6
49JNJ-38518168----1件: 46
50JNJ-38518168 (10 mg)----1件: 46
51JNJ-38518168 (3 mg)----1件: 46
52JNJ-38518168 (30 mg)----1件: 46
53JNJ-38518168 / MTX----1件: 46
54JNJ-38518168 50-mg Over Encapsulated Tablet----1件: 46
55JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg----1件: 46
56JNJ-38518168-ZBQ----1件: 46
57JNJ-38518168-ZBQ - film-coated tablet - 10 mg----1件: 46
58JNJ-38518168-ZBQ - film-coated tablet - 10mg----1件: 46
59JNJ-38518168-ZBQ - film-coated tablet - 3 mg----1件: 46
60JNJ-38518168-ZBQ - film-coated tablet - 30 mg----1件: 46
61JNJ-38518168-ZBQ - film-coated tablet - 30mg----1件: 46
62JNJ-38518168-ZBQ - film-coated tablet - 3mg----1件: 46
63JNJ-39039039----1件: 210
64JNJ-39758979----1件: 46
65JNJ-39758979 (10 mg)----1件: 46
66JNJ-39758979 (100 mg)----1件: 46
67JNJ-39758979 (30 mg)----1件: 46
68JNJ-39758979 (300 mg)----1件: 46
69JNJ-39758979 / MTX----1件: 46
70JNJ-39758979-AAC - enteric coated tablet - 10 mg----1件: 46
71JNJ-39758979-AAC - enteric coated tablet - 100 mg----1件: 46
72JNJ-39758979-AAC - enteric coated tablet - 30 mg----1件: 46
73JNJ-403465271件: JNJ-40346527---2件: 46, 96
74JNJ-40346527-AAC1件: JNJ-40346527---1件: 96
75JNJ-40346527-AAC - capsule - 50 mg1件: JNJ-40346527---1件: 46
76JNJ-42160443----1件: 226
77JNJ-54767414----2件: 28, 49
78JNJ-54781532 150 mg once daily----1件: 97
79JNJ-54781532 25 mg once daily----1件: 97
80JNJ-54781532 75 mg once daily----1件: 97
81JNJ-54781532 75 mg twice daily----1件: 97
82JNJ-54781532-AAD-10 mg----1件: 97
83JNJ-54781532-AAD-30 mg----1件: 97
84JNJ-54781532-AAD-5 mg----1件: 97
85JNJ-55920839----1件: 49
86JNJ-56022473----1件: 49
87JNJ-64304500----1件: 96
88JNJ-64304500-AAA----1件: 96
89JNJ-64841829----1件: 97
90JNJ-64841842----1件: 97
91JNJ-64841855----1件: 97
92JNJ-64841894----1件: 97
93JNJ-64841907----1件: 97
94JNJ-64841920----1件: 97
95JNJ-64841933----1件: 97
96JNJ-64841946----1件: 97
97JNJ-66525433----1件: 97
98JNJ-67484703----1件: 46
99JNJ-67864238----1件: 96
100JNJ-67896049----1件: 86
101JNJ-67896049 (ACT-293987)----1件: 86
102JNJ-67896062 / ACT-064992----2件: 86, 88
103JNJ-67896062/ ACT-064992----2件: 86, 88
104JNJ-67896062/ACT-064922----1件: 86
105JNJ-67896153/ACT-128800----1件: 13
106JNJ-72537634----1件: 97
107JNJ-78934804----2件: 96, 97
108JNJ-80202135----4件: 11, 46, 49, 53
109JNJ31-31001074----1件: 6
110Joint puncture----1件: 107
111Jojoba oil1件: Jojoba oil---1件: 36
112Jojoba oil with broccoli sprout extract2件: Broccoli,
Jojoba oil		---1件: 36
113Jorveza1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
114Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
115Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
116Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
117Jorveza 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
118JP 1730----1件: 6
119JP-1730/F01----2件: 6, 17
120JP-1730/F02----2件: 6, 17
121JP-1730/F03----2件: 6, 17
122JR-141----1件: 19
123JR-141 or Idursulfase1件: Idursulfase1件: D04499 1件: IDS 💬3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬1件: 19
124JR-171 (lepunafusp alfa)----1件: 19
125JS002----1件: 79
126JS005----1件: 271
127JSP191----2件: 65, 285
128JTE-051----1件: 46
129JTT-251----1件: 86
130Juanbi pill----1件: 46
131Juvit D3----1件: 6
132Jyseleca1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
133Jyseleca 100 mg film-coated tablets1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
134Jyseleca 200 mg film-coated tablets1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
135JZP-110----1件: 6